Effectiveness Evaluation of the Sinopharm Vaccine in the Dondo District in Mozambique

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-02-24

Study Completion Date

2024-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Three complementary activities will be implemented:1) Baseline and repeat census of the catchment population; described in a separate protocol (IVI-ECOVA-03-WS1); 2) Enhanced surveillance for COVID-19 disease, and 3) AEFI-enhanced surveillance. The mass vaccination campaign will be conducted by the Government and is not part of this protocol.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

COVID-19 Surveillance in Rural Mozambique for Prompt and Effective Response

NCT05228639

COVID-19

COMPLETED

Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines

NCT04998240

Covid19

UNKNOWN PHASE2

Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania

NCT00513669

Falciparum Malaria

COMPLETED PHASE1

Plasmodium Falciparum Genomic Intelligence in Mozambique

NCT05306067

Malaria,Falciparum Malaria in Pregnancy Malaria

COMPLETED

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria

NCT07235020

Uncomplicated Plasmodium Falciparum Malaria

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sars-CoV-2 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

ECOLOGIC_OR_COMMUNITY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Case

Sinopharm Vaccine

Intervention Type OTHER

Sinopharm Vaccine will be administered by the Govt as part of COVID-19vaccination campaign

Test Negative Control

Sinopharm Vaccine

Intervention Type OTHER

Sinopharm Vaccine will be administered by the Govt as part of COVID-19vaccination campaign

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sinopharm Vaccine

Sinopharm Vaccine will be administered by the Govt as part of COVID-19vaccination campaign

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. They resided in the study area at the time of mass immunization with the Sinopharm vaccine; and
2. They are at least 18 years of age during first round of mass vaccination.
3. Their onset of symptoms was \<10 days prior to testing.
4. For each selected PCR test-positive case, we will select up to 3 test-negative controls from generally eligible subjects, matched to each case by age on the date of testing, sex, and calendar date of testing + 3 days.